Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Eiger BioPharmaceuticals, Inc. | d53576dex321.htm |
| 10-K - FORM 10-K - Eiger BioPharmaceuticals, Inc. | d53576d10k.htm |
| EX-21.1 - EX-21.1 - Eiger BioPharmaceuticals, Inc. | d53576dex211.htm |
| EX-31.2 - EX-31.2 - Eiger BioPharmaceuticals, Inc. | d53576dex312.htm |
| EX-32.2 - EX-32.2 - Eiger BioPharmaceuticals, Inc. | d53576dex322.htm |
| EX-31.1 - EX-31.1 - Eiger BioPharmaceuticals, Inc. | d53576dex311.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-203153) of Celladon Corporation, |
| (2) | Registration Statement (Form S-8 No. 333-203154) pertaining to the 2013 Equity Incentive Plan, 2013 Employee Stock Purchase Plan and Inducement Grants, and |
| (3) | Registration Statement (Form S-8 No. 333-193662) pertaining to the 2001 Stock Option Plan, 2012 Equity Incentive Plan, 2013 Equity Incentive Plan, and 2013 Employee Stock Purchase Plan; |
of our report dated March 30, 2016, with respect to the consolidated financial statements of Celladon Corporation included in this Annual Report (Form 10-K) of Eiger BioPharmaceuticals, Inc. (formerly Celladon Corporation) for the year ended December 31, 2015.
/s/ Ernst & Young LLP
San Diego, California
March 30, 2016